Detalles de la búsqueda
1.
Characterization of Viruses in Phase 3 and Phase 3b Trials (the Ring Study and the Dapivirine Ring Extended Access and Monitoring Trial) of the Dapivirine Vaginal Ring for Human Immunodeficiency Virus Type 1 Infection Risk Reduction.
Clin Infect Dis
; 76(6): 996-1002, 2023 03 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36345569
2.
Clinical Presentation, Treatment Response, and Virology Outcomes of Women Who Seroconverted in the Dapivirine Vaginal Ring Trials-The Ring Study and DREAM.
Clin Infect Dis
; 76(3): 389-397, 2023 02 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36189636
3.
Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women.
N Engl J Med
; 375(22): 2133-2143, 2016 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27959766
4.
Phase 1 randomized trials to assess safety, pharmacokinetics, and vaginal bleeding associated with use of extended duration dapivirine and levonorgestrel vaginal rings.
PLoS One
; 19(6): e0304552, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38838028
5.
Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial.
Lancet HIV
; 10(12): e779-e789, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37898146
6.
A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study).
AIDS Res Hum Retroviruses
; 38(4): 269-278, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34384282
7.
Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United States.
J Int AIDS Soc
; 24(6): e25747, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34118115
8.
Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study.
Lancet HIV
; 8(2): e77-e86, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33539761
9.
Analysis of Site Heterogeneity and HIV Outcomes Across Rural and Urban Study Sites in Phidisa II - A Multi-site Randomized Controlled Antiretroviral Treatment Trial in a South African Military Cohort.
Curr HIV Res
; 15(3): 178-187, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28521717
Resultados
1 -
9
de 9
1
Próxima >
>>